Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 26, 2026

7 Signs Your 401(k) Is Quietly Underperforming

View original at finance.yahoo.com
7 Signs Your 401(k) Is Quietly Underperforming Quick Read iShares Core S&P 500 ETF (IVV) charges an expense ratio of 0.03%, the benchmark for low-cost index investing, while many 401(k) plans offer index-style funds charging over 0.5%—a gap that compounds into six-figure losses on a $500,000 balance over 20 years…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • A $100,000 investment at a 7% gross annual return can grow substantially over 20 years at near-zero fees, while a 1% expense ratio meaningfully reduces that outcome

    60% confidence
  • Actively managed funds charge more and, over long periods, most underperform their benchmark indexes after fees

    60% confidence
  • Staying in a low-yielding default option while equity markets compound is one of the most expensive passive decisions a retirement saver can make

    60% confidence
  • Many 401(k) plans offer index-style funds charging over 0.5%, a gap that compounds into six-figure losses on a $500,000 balance over 20 years compared to iShares Core S&P 500 ETF's 0.03% expense ratio

    60% confidence
  • Target-date funds from high-fee providers charge 0.6% to 0.8% annually compared to under 0.15% for low-cost alternatives

    60% confidence
  • Most 401(k) account holders unknowingly lose wealth through structural problems like excessive fees, concentrated employer stock positions above 10%, drift from target allocations, and failure to rebalance—costing participants tens of thousands in foregone compounding

    60% confidence

Data points we hold from this source

Board of Governors of the Federal Reserve System · federal funds rate3.75 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
7 Signs Your 401(k) Is Quietly Underperforming — Source | Via News | Via News